Physician profile

Ashley B Frederick

Family · Florence, AL

NPI 1548921554

$552.92

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$400.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $267.00 2022-2024
Lilly USA, LLC $104.07 2022-2024 Mounjaro
Ibsa Pharma INC. $50.01 2022-2024 Tirosint, Licart, Tirosint
Halozyme INC $47.68 2023
Shield Therapeutics INC $19.30 2023 Accrufer
Scynexis, INC. $18.68 2022
Antares Pharma, INC. $16.72 2023 Tlando, Xyosted, Nocdurna
Daiichi Sankyo INC. $16.13 2022
Novo Nordisk INC $13.33 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ashley B Frederick

$552.92

in general payments reported 2019-2025

Years
2022-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/11310682/ashley-b-frederick

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.